Earlier-generation, non-selective JAK inhibitors have carried FDA safety warnings. Selective JAK inhibitors are designed to overcome these risks,² and Impetis’s preclinical data demonstrate clear differentiation from older drugs in the class.¹ While VT-1953 for malignant fungating wounds remains Vyome’s lead program, these assets extend the company’s portfolio into large immuno-inflammatory therapeutic areas. That market is expected to exceed $430 billion by 2034,³ with the JAK inhibitor segment alone representing a ~$57 billion opportunity.⁴

The transaction highlights the strength of the US–India innovation corridor in sourcing high-quality assets efficiently. It is structured to be highly capital-efficient, with consideration tied to commercialization, and any future development will be pursued through non-dilutive pathways.¹